期刊文献+

代谢综合征对冠心病血运重建患者预后的影响 被引量:2

Effect of metabolic syndrome on prognosis of revascularization in patients with coronary artery disease
原文传递
导出
摘要 目的 探讨集中了5个心血管病危险因素(肥胖、糖代谢异常、高血压、高甘油三酯血症、低高密度脂蛋白胆固醇血症)的代谢综合征在冠心病患者中的流行趋势和预后意义.方法 研究对象来自单中心注册研究DESIRE(drug-eluting stent impact on revascularization),入选2003年7月1日至2004年9月30日在首都医科大学附属安贞医院接受血运重建治疗[经皮冠状动脉介入(PCI)或冠状动脉旁路移植术(CABG)]的2368例患者,选择其中身高、体重、血压、血糖和血脂等记录完整的患者共1911例,平均年龄(60±10)岁,记录其临床资料及随访期间临床不良事件,患者死亡为随访终止,记录死亡时间.代谢综合征定义采用2005年美国胆固醇教育计划成人治疗专家组修订(NCEP ATP Ⅲ)的定义,以体重指数(BMI)≥25 kg/m2代替腹围指标.计量资料均值应用-x±s表示,两组间比较采用t检验,多组间比较采用方差分析,计数资料采用x2检验,不良事件与代谢综合征患者的相关性应用Logistic和Cox回归分析.结果 相应临床资料记录完整的患者1911例,其中男性1458例占76.3%.截至2007年底随访时间中位数为3.5年(293~1855 d).按照是否合并代谢综合征将患者分为2组,发现合并代谢综合征对住院期间和随访期间的死亡率没有影响,但明显增加随访期间主要不良心脑血管事件(MACCE)的发生率(P<0.05).随访3.5年,合并代谢综合征患者增加的MACCE事件主要表现在:再次血运重建事件、脑卒中事件和再入院事件(P<0.05);把性别、年龄、血脂等心血管危险因素放入Logistic模型中,比较影响总MACCE发生的危险因素,仅发现合并代谢综合征是影响总MACCE发生的惟一因素(OR 1.319,95%CI 1.020~1.706,P<0.05).应用Logistic回归分析代谢综合征5个组成成分对随访MACCE的影响,发现糖代谢异常(OR 1.047,95% CI 1.005~1.091,P<0.05)和低高密度脂蛋白胆固醇血症(OR 0.777,95%CI0.610~0.989,P<0.05)是影响预后的主要因素.同时发现无论是否合并糖尿病,代谢综合征对3.5年随访MACCE事件均有显著的预测意义(合并糖尿病人群中:OR 1.516,95%CI1.062~2.159,P<0.05;无糖尿病人群中:OR1.398,95%CI1.021~2.092,P<0.05),只是比值比在未合并糖尿病的冠心病患者中略有降低.结论 在冠心病血运重建患者中,代谢综合征可以预测冠心病患者的不良预后,无论是否合并糖尿病,代谢综合征对随访MACCE事件都有显著的预测意义.
出处 《中华糖尿病杂志》 CAS 2010年第6期-,共6页 CHINESE JOURNAL OF DIABETES MELLITUS
基金 国家重点基础研究发展规划资金资助项目
  • 相关文献

参考文献14

  • 1Isomaa B,Almgren P,Tuomi T. Cardiovascular morbidity and mortality associated with the metabolic syndrome[J].Diabetes Care,2001,(4):683-689.doi:10.2337/diacare.24.4.683.
  • 2Klein BE,Klein R,Lee KE. Components of metabolic syndrome and the risk of cardiovascular diseases and diabetes in beaver dam[J].Diabetes Care,2002,(10):1790-1794.doi:10.2337/diacare.25.10.1790.
  • 3Expert panel on detection evaluation and treatment of high blood cholesterol in adults. Executive summary of the third report of the national cholesterol education program (NCEP) adult treatment panel Ⅲ[J].Journal of the American Medical Association,2001.2486-2497.
  • 4Gazzaruso C,Solerte SB,De Amici E. Association of the metabolic syndrome and insulin resistance with silent myocardial ischemia in patients with type 2 diabetes mellitus[J].American Journal of Cardiology,2006.236-239.doi:10.1016/j.amjcard.2005.07.133.
  • 5Rider PM,Buring JE,Cook NR. C-reactive protein,the metabolic syndrome and risk of incident cardiovascular event:an 8-year follow-up of 14 719 initially health American woman[J].Circulation,2003.391-397.
  • 6Hoshino A,Nakamura T,Enomoto S. Prevalence of coronary artery disease in Japanese patients with cerebral infarction:impact of metabolic syndrome and intracranial large artery atherosclerosis[J].Circulation,2008.404-408.
  • 7Anderson JL,Home BD,Jones HU. Which features of the metabolic syndrome predict the prevalence and clinical outcomes of angiographic coronary artery disease[J].Cardiology,2004,(4):185-193.doi:10.1159/000076695.
  • 8Nigam A,Bourassa MG,Fortier A. The metabolic syndrome and its components and the long-term risk of death in patients with coronary heart disease[J].American Heart Journal,2006.514-521.doi:10.1016/j.ahj.2005.03.050.
  • 9Lin RT,Lee WJ,Jeng CY. Metabolic syndrome and its contribution to coronary artery disease in non-diabetic subjects[J].Journal of the Formosan Medical Association,2004,(4):317-320.
  • 10Nilsson PM,Engstr(o)m G,Hedblad B. Metabolic syndrome and incidence of cardiovascular disease in non-diabetic subjects-a population-based study comparing three different definitions[J].Diabetic Medicine,2007.464-472.doi:10.1111/j.1464-5491.2007.02142.x.

同被引文献18

  • 1兰亚明.糖尿病合并冠心病患者药物洗脱支架术后应用氯吡格雷的疗效[J].中国老年学杂志,2015,35(1):65-68. 被引量:23
  • 2董剑廷,袁勇,邓志华,张励庭,黄炫生,韩莹,刘卫其,林素清,吴惠玉.代谢综合征患者冠状动脉病变特点的病例对照研究[J].中国基层医药,2005,12(10):1301-1302. 被引量:4
  • 3朱文华,方力争,孟文芳,陈建华.急性心脑血管事件与代谢综合征的相关性研究[J].中华急诊医学杂志,2006,15(2):168-170. 被引量:6
  • 4胡荣,聂绍平,杜昕,吕强,康俊萍,张崟,梁金鑫,郝鹏,王苏,刘彤,吴学思,董建增,刘晓惠,马长生.代谢综合征在非ST段抬高急性冠脉综合征患者中的临床特点及近期预后[J].中华急诊医学杂志,2006,15(6):529-532. 被引量:7
  • 5Gorter PM, Olijhoek JK, Vander G~. The SMART Study Group, 2004, Prevalence of the metabolic syndrome in patients with coronary heart disease, cerebrovascular disease, peripheral arterial disease or abnormal aortic aneurysm [ J ]. Atherosclerosis, 2004, 173 (2): 363-369.
  • 6Solymoss BC, Brourassa MG, Lesperance J, et al. Incidence and clinical characteristics of the metabolic syndrome in patients with coronary heart disease [ J], Coron Artery Dis, 2003, 14 (3) : 207 -212.
  • 7Kasai T, Miyauchi K, Kurata T, et al. Prognostic value of metabolic syndrome for long-term outcomes in patients undergoing percutanceous coronary intervention [ J ]. Circ J, 2006, 70 (12) : 1531-1537.
  • 8Tantan Z, Ozer N, Uyarel H, et al. Metabolic syndrome is a predictor for an ECG sign of no-reflow after primary PCI in patients with acute ST-elevation myocardial infraction [ J ]. Nutr Metab Cardiovasc Dis. 2005, 18 (6) : 441-447.
  • 9Rana JS, Monraats JW, Jukema MP, et al. Metabolic syndrome and risk of restenosis in patients undergoing percutaneous coronary intervention [J]. Diabetes Care, 2005, 28 (4) : 873-877.
  • 10Hoffman R, Stellbrink E, Radke PW, et al. Impact of metabolic syndrome on angiographic and clinical events after coronary intervention using bare metal of sirolimus eluting stents [J]. Am J Cardiol, 2007, 100 (9) : 1347-1352.

引证文献2

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部